SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-24-003344
Filing Date
2024-01-05
Accepted
2024-01-05 16:01:33
Documents
17
Period of Report
2023-10-20
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d109820d8ka.htm   iXBRL 8-K/A 32237
2 EX-23.1 d109820dex231.htm EX-23.1 1866
3 EX-99.1 d109820dex991.htm EX-99.1 357383
4 EX-99.2 d109820dex992.htm EX-99.2 302041
5 EX-99.3 d109820dex993.htm EX-99.3 181358
  Complete submission text file 0001193125-24-003344.txt   1141301

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA qncx-20231020.xsd EX-101.SCH 3879
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE qncx-20231020_def.xml EX-101.DEF 14089
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20231020_lab.xml EX-101.LAB 23388
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20231020_pre.xml EX-101.PRE 15122
11 EXTRACTED XBRL INSTANCE DOCUMENT d109820d8ka_htm.xml XML 7103
Mailing Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38890 | Film No.: 24516165
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)